Eagle Pharmaceuticals Inc (EGRX) — Financial Flexibility Index
Eagle Pharmaceuticals Inc (EGRX) has a Financial Flexibility Index of 0.00x as of June 2023. Free cash flow of $-120.00K (operating CF $-126.00K minus capex $6.00K) represents 0% of total liabilities ($152.78 Million). Check EGRX total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Eagle Pharmaceuticals Inc Financial Flexibility Index (2012–2022)
Historical Financial Flexibility Index trend for Eagle Pharmaceuticals Inc across 11 annual periods. For the full cash flow conversion analysis, see EGRX cash generation efficiency.
Annual Financial Flexibility Index for Eagle Pharmaceuticals Inc (2012–2022)
Year-by-year free cash flow to debt coverage for Eagle Pharmaceuticals Inc. Explore debt repayment capacity of Eagle Pharmaceuticals Inc to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2022 | 0.18x | $30.98 Million | $30.80 Million | $172.60 Million | ▼ -51.4% |
| 2021 | 0.37x | $28.54 Million | $28.22 Million | $77.28 Million | ▼ -50.6% |
| 2020 | 0.75x | $50.24 Million | $49.50 Million | $67.18 Million | ▼ -0.7% |
| 2019 | 0.75x | $56.76 Million | $55.99 Million | $75.38 Million | ▲ +11.6% |
| 2018 | 0.67x | $52.52 Million | $52.38 Million | $77.84 Million | ▼ -4.3% |
| 2017 | 0.71x | $64.11 Million | $58.92 Million | $90.92 Million | ▼ -40.5% |
| 2016 | 1.19x | $73.90 Million | $53.21 Million | $62.34 Million | ▲ +618.2% |
| 2015 | -0.23x | $-7.84 Million | $-9.72 Million | $34.26 Million | ▲ +66.3% |
| 2014 | -0.68x | $-13.80 Million | $-13.84 Million | $20.32 Million | ▼ -86.7% |
| 2013 | -0.36x | $-5.84 Million | $-5.88 Million | $16.05 Million | ▲ +49.5% |
| 2012 | -0.72x | $-15.52 Million | $-15.55 Million | $21.54 Million | — |